

approval under the Paperwork Reduction Act of 1995.

**SUMMARY:** In accordance with requirements of the Paperwork Reduction Act of 1995 (44 U.S.C. Chapter 35), the Board of Governors of the Federal Reserve System (Board) hereby gives notice that it has submitted to the Office of Management and Budget (OMB) a request for approval of the information collection system described below. The Federal Reserve may not conduct or sponsor, and the respondent is not required to respond to, an information collection that has been extended, revised, or implemented on or after October 1, 1995, unless it displays a currently valid OMB control number.

**DATES:** Comments must be submitted on or before March 18, 1996.

**ADDRESSES:** Comments, which should refer to the OMB control number, should be addressed to the OMB desk officer for the Board: Milo Sunderhauf, Office of Information and Regulatory Affairs, Office of Management and Budget, New Executive Office Building, Room 3208, Washington, DC 20503. Comments should also be addressed to Mr. William W. Wiles, Secretary, Board of Governors of the Federal Reserve System, 20th and C Streets, N.W., Washington, DC 20551, or delivered to the Board's mail room between 8:45 a.m. and 5:15 p.m., and to the security control room outside of those hours. Both the mail room and the security control room are accessible from the courtyard entrance on 20th Street between Constitution Avenue and C Street, N.W. Comments received may be inspected in room M-P-500 between 9:00 a.m. and 5:00 p.m., except as provided in section 261.8 of the Board's Rules Regarding Availability of Information, 12 CFR 261.8(a).

**FOR FURTHER INFORMATION CONTACT:** A copy of the Paperwork Reduction Act Submission (OMB 83-I), supporting statement, and other documents that have been submitted to OMB for review and approval may be requested from the agency clearance officer, whose name appears below. Mary M. McLaughlin, Federal Reserve Board Clearance Officer (202-452-3829), Division of Research and Statistics, Board of Governors of the Federal Reserve System, Washington, DC 20551. Telecommunications Device for the Deaf (TDD) users may contact Dorothea Thompson (202-452-3544), Board of Governors of the Federal Reserve System, Washington, DC 20551.

Proposal to request approval from OMB of the extension, with revision, of the following report:

*1. Report title:* Report of Assets and Liabilities of U.S. Branches and Agencies of Foreign Banks  
*Agency form number:* FFIEC 002  
*OMB control number:* 7100-0032  
*Frequency:* Quarterly  
*Reporters:* U.S. branches and agencies of foreign banks  
*Annual reporting hours:* 48,653  
*Estimated average hours per response:* 22.40  
*Number of respondents:* 543  
Small businesses (that is, small U.S. branches and agencies of foreign banks) are affected.

*General description of report:* This information collection is mandatory [12 U.S.C. 3105(b)(2), 1817(a)(1) and (3), and 3102(b)]. Except for select sensitive items, this information collection is not given confidential treatment (5 U.S.C. 552(b)(8)).

*Abstract:* On December 11, 1995, the three agencies jointly published a notice in the Federal Register (60 FR 63526) describing in detail and inviting comment on the proposed changes to this collection of information. All comments received by the agencies in response to that notice, including a change to the proposed revisions that the agencies made in response to those comments, were addressed in supporting statements that were developed to justify the proposed changes. This notice provides the public with the opportunity to obtain, review, and comment on, the Board's supporting statement.

Board of Governors of the Federal Reserve System, February 12, 1996.

William W. Wiles,

*Secretary of the Board.*

[FR Doc. 96-3548 Filed 2-15-96; 8:45AM]

Billing Code 6210-01-F

### **Forrest Bancshares, Inc.; Formation of, Acquisition by, or Merger of Bank Holding Companies**

The company listed in this notice has applied for the Board's approval under section 3 of the Bank Holding Company Act (12 U.S.C. 1842) and § 225.14 of the Board's Regulation Y (12 CFR 225.14) to become a bank holding company or to acquire a bank or bank holding company. The factors that are considered in acting on the applications are set forth in section 3(c) of the Act (12 U.S.C. 1842(c)).

The application is available for immediate inspection at the Federal Reserve Bank indicated. Once the application has been accepted for processing, it will also be available for inspection at the offices of the Board of Governors. Interested persons may

express their views in writing to the Reserve Bank indicated for that application or to the offices of the Board of Governors. Any comment on an application that requests a hearing must include a statement of why a written presentation would not suffice in lieu of a hearing, identifying specifically any questions of fact that are in dispute and summarizing the evidence that would be presented at a hearing.

Comments regarding this application must be received not later than March 11, 1996.

A. Federal Reserve Bank of Chicago (James A. Bluemle, Vice President) 230 South LaSalle Street, Chicago, Illinois 60690:

*1. Forrest Bancshares, Inc.,* Forrest, Illinois; to merge with Erie Bancorp, Inc., Erie, Illinois, and thereby indirectly acquire Erie State Bank, Erie, Illinois.

Board of Governors of the Federal Reserve System, February 12, 1996.

Jennifer J. Johnson,

*Deputy Secretary of the Board.*

[FR Doc. 96-3547 Filed 2-15-96; 8:45 am]

BILLING CODE 6210-01-F

### **GENERAL ACCOUNTING OFFICE**

#### **Notice of Transmittal of the United States General Accounting Office Compliance Report to the President and the Congress Covering Reports and Presidential Orders Issued During the Session of Congress Ending on January 3, 1996, Reporting and Recording Requirements**

**AGENCY:** General Accounting Office.

**ACTION:** Notice.

**SUMMARY:** The United States General Accounting Office has submitted its compliance report covering reports and presidential orders issued during the session of Congress ending on January 3, 1996, to the President of the United States, the President of the Senate, and the Speaker of the House of Representatives.

**SUPPLEMENTARY INFORMATION:** Under the Omnibus Budget Reconciliation Act of 1990, as amended, 2 U.S.C. sec. 904(b), one day following issuance of its compliance report, the General Accounting Office must announce a notice of the report in the Federal Register.

Susan J. Irving,

*Associate Director, Budget Issues, Accounting and Information Management Division.*

[FR Doc. 96-3502 Filed 2-15-96; 8:45 am]

BILLING CODE 1610-01-M

**DEPARTMENT OF HEALTH AND HUMAN SERVICES****National Institutes of Health****Government-Owned Inventions; Availability for Licensing**

**AGENCY:** National Institutes of Health, HHS.

**ACTION:** Notice.

The inventions listed below are owned by agencies of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of federally funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for U.S. companies and may also be available for licensing.

**ADDRESSES:** Licensing information and copies of the U.S. patent applications listed below may be obtained by writing to Carol Lavrich, Technology Licensing Specialist, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804 (telephone 301/496-7735 ext 287; fax 301/402-0220). A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications.

**Methods for Treating Autoimmune Diseases and Transplantation Rejection**

Singer, D.S., Kohn, L.D., Mozes, E., Saji, M. (NCI)

Serial No. 08/503,525 filed 21 Aug 95 (CIP of 08/480,525) and Serial No. 08/464,130 filed 7 Jun 95 (DIV of 08/073,830)

Methods for treating autoimmune diseases in mammals and for preventing or treating transplantation rejection in a transplant recipient are described in this invention. The invention relates to methods for treating and preventing these diseases, using drugs capable of suppressing expression of the major histocompatibility complex (MHC) Class I molecules. The invention further includes method for *in vivo* and *in vitro* assays, for the development and assessment of drugs capable of suppressing expression of MHC Class I molecules. Furthermore, the invention provides a method for preventing rejection of cells containing a recombinant gene transplanted into a mammal in need of a gene therapy. (portfolio: Internal Medicine—Therapeutics, anti-inflammatory)

**Methods for Treating Autoimmune Diseases and Transplantation Rejection**

Singer, D.S., Kohn, L.D., Mozes, E., Saji, M. (NCI)

Filed 7 Jun 95

Serial No. 08/480,525 (FWC of 08/073,830)

Methods for treating autoimmune diseases by suppressing the expression of the major histocompatibility complex (MHC) class I molecules by administering either methimazole, methimazole derivatives, carbimazole, propylthiouracil, thionamides, thiouretylenes, thioureas, and thiourea derivatives. These compounds can be used to treat diseases such as rheumatoid arthritis, psoriasis, juvenile diabetes, primary idiopathic myxedema, myasthenia gravis, scleroderma, De Quervains thyroiditis, systemic lupus erythematosus dermatomyositis, polyarteritis nodosa, and polymyositis. This invention also provides the means for inhibiting transplantation rejection in humans. Also provided are *in vivo* and *in vitro* means for assessing and developing drugs capable of suppressing the MHC class I molecules. (portfolio: Internal Medicine—Therapeutics, anti-inflammatory)

**Mutants Having a Deficit of Functional Steroid Hormone Receptors**

Korach, K.S. (NIEHS)

Filed 7 June 95

Serial Number 08/480,854

This invention concerns "knockout" animals, including mice, which have a deficit of functional steroid hormone receptors, DNA constructs containing the mutations, and methods for producing the animals. The mutation is introduced into the animal or its ancestors at an embryonic stage. These knockout animals provide a model system for studying the biological role of hormones, including steroid hormones and sex steroids, in growth, development, morphological differentiation, and sexual and reproductive behavior and cycles, etc. More specifically, the animals may serve as models for testing sex hormones and synthetics that mimic or antagonize sex hormones for use in birth control methods or as hormone replacement therapies. In addition, they provide a system for the characterization of materials suspected of precipitating or conferring protection against osteoporosis, cardiovascular disease, breast cancer, endometrial cancer, and other cancers. (portfolio: Internal Medicine—Miscellaneous)

**Nitroxides as Protectors Against Oxidative Stress**

Mitchell, J.B., Samui, A., DeGraff, W., Hahn, S. (NCI)

Filed 7 Jun 95

Serial No. 08/473,960 (CIP of 07/859,622, U.S. Patent 5,462,946 issued 31 Oct 95; CON of 07/494,532)

New metal-independent nitroxide compounds are antioxidants capable of protecting cells, tissues, and organs against the harmful effects of toxic oxygen-related species (hydroxyl radical, hydrogen peroxide, superoxide). These toxic oxygen-related species have been implicated in tissue damage from ionizing radiation, reperfusion injury, adult respiratory distress syndrome, inflammation, and agents involved in such processes as carcinogenesis and aging. These mimetic agents have several advantages over natural antioxidants such as superoxide dismutase in that they can exert protection inside the cell since they are small and uncharged. Additionally, long-term administration of these agents to animals induces weight reduction without untoward effects. (portfolio: Internal Medicine—Miscellaneous)

**Heparin—and Sulfatide-Binding Peptides From the Type I Repeats of Human Thrombospondin**

Roberts, D.D., Browning, P.J., Bryant, J., Inman, J.K., Krutzsch, H.C., Guo, N. (NCI)

Filed 21 Mar 94

Serial No. 08/215,085 (CIP of 07/801,812, U.S. Patent 5,357,041 issued 18 Oct 94)

This invention describes a new family of related peptides that bind with high affinity to heparin or to heparin sulfate proteoglycans and inhibit specific functions of these molecules. The peptides thus are antagonists of basic fibroblast growth factor. Some of the peptides contain a second sequence that mediates activation of transforming growth factor- $\beta$ . Stable analogs of these peptides have been prepared that resist proteolysis and retain activity *in vivo*. The ability of these peptides to modulate tumor growth and angiogenesis has been demonstrated, and suggest that they might be useful as cancer therapeutic agents. Furthermore, the peptides may be useful for promoting adhesion to substrates coated with the peptides. The novel compounds, which are derived from the adhesive protein thrombospondin, have binding constants 10 to 100 times greater than those of currently available inhibitors; in addition, the heparin-binding sequence does not require an ionic charge, thus making them suitable

for pharmaceutical preparations. It is expected that the high potency of these agents will lower the effective dose needed, and, subsequently, will reduce the immunological response against the peptides and the risks of toxicity. (portfolio: Internal Medicine—Therapeutics, anti-inflammatory)

Peptide Derivatives of Cytochrome b558 and Their Use as Medicaments [as Anti-Inflammatory Agents]

Malech, H., Rotrosen, D. (NIAID)  
Filed 24 May 90  
Serial No. 07/527,767 (CIP of 07/  
331,652)

Licensing Contact: Carol Lavrich, 301/  
496-7735 ext 287

A new anti-inflammatory agent based on two c-terminal amino acid sequences of cytochrome b558 has been shown to inhibit the production of toxic oxygen products (superoxide, peroxide) by human phagocytic cells. Because of its specificity for phagocytic cells, it is expected that these peptide derivatives would not have the side effects of other anti-inflammatory agents in general use. (portfolio: Internal Medicine—Therapeutics, anti-inflammatory)

Dated: February 5, 1996.

Barbara M. McGarey,

*Deputy Director, Office of Technology Transfer.*

[FR Doc. 96-3517 Filed 2-15-96; 8:45 am]

BILLING CODE 4140-01-M

### National Institute on Deafness and Other Communication Disorders; Notice of Closed Meeting

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 United States Code, Appendix 2), notice is hereby given of the following meeting:

*Name of Committee:* National Institute on Deafness and Other Communication Disorders Special Emphasis Panel.

*Date:* February 28, 1996.

*Time:* 1:00-2:30 p.m.

*Place:* Room 400C, 6120 Executive Blvd., Rockville, MD 20852 (telephone conference call).

*Contact Person:* Marilyn Semmes, Ph.D., Acting Chief, Scientific Review Administrator, NIDCD/DEA/SRB, EPS Room 400C, 6120 Executive Boulevard, MSC 7180, Bethesda, MD 20892-7180, 301-496-8683.

*Purpose/Agenda:* To review and evaluate grant applications.

The meeting will be closed in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5, United States Code. The applications and/or proposals and the discussion could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals

associated with the applications and/or proposals, the disclosure of which could constitute a clearly unwarranted invasion of personal privacy.

This notice is being published less than fifteen days prior to the meeting due to the urgent need to meet timing limitations imposed by the grant review cycle.

(Catalog of Federal Domestic Assistance Program No. 93.173 Biological Research Related to Deafness and Communication Disorders)

Dated: February 12, 1996.

Susan K. Feldman,

*Committee Management Officer, NIH.*

[FR Doc. 96-3516 Filed 2-15-96; 8:45 am]

BILLING CODE 4140-01-M

### National Institute of Dental Research; Notice of Closed Meeting of the National Institute of Dental Research Special Grants Review Committee

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting:

*Name of Committee:* National Institute of Dental Research Special Grants Review Committee.

*Date:* March 26-28, 1996.

*Time:* 8:30 a.m. to Adjournment.

*Place:* Hilton Hotel, 620 Perry Parkway, Gaithersburg, Maryland 20877.

*Contact Person:* Dr. William Gartland, Scientific Review Administrator, NIDR Special Grants Review Committee, Natcher Building, Room 4AN-38E, Bethesda, MD 20892, (301) 594-2372.

*Purpose/Agenda:* To review and evaluate grant applications and/or contract proposals.

The meeting will be closed in accordance with the provisions set forth in secs. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance Program No. 93.121, Dental Research Institute; National Institutes of Health, HHS)

Dated: February 12, 1996.

Susan K. Feldman,

*Committee Management Officer, NIH.*

[FR Doc. 96-3515 Filed 2-15-96; 8:45 am]

BILLING CODE 4140-01-M

## DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT

### Office of the Assistant Secretary for Community Planning and Development

[Docket No. FR-3778-N-72]

### Federal Property Suitable as Facilities to Assist the Homeless

**AGENCY:** Office of the Assistant Secretary for Community Planning and Development, HUD.

**ACTION:** Notice.

**SUMMARY:** This Notice identifies unutilized, underutilized, excess, and surplus Federal property reviewed by HUD for suitability for possible use to assist the homeless.

#### FOR FURTHER INFORMATION CONTACT:

Mark Johnston, room 7256, Department of Housing and Urban Development, 451 Seventh Street SW, Washington, DC 20410; telephone (202) 708-1226; TDD number for the hearing- and speech-impaired (202) 708-2565 (these telephone numbers are not toll-free), or call the toll-free Title V information line at 1-800-927-7588.

#### SUPPLEMENTARY INFORMATION:

In accordance with 24 CFR part 581 and section 501 of the Stewart B. McKinney Homeless Assistance Act (42 U.S.C. 11411), as amended, HUD is publishing this Notice to identify Federal buildings and other real property that HUD has reviewed for suitability for use to assist the homeless. The properties were reviewed using information provided to HUD by Federal landholding agencies regarding unutilized and underutilized buildings and real property controlled by such agencies or by GSA regarding its inventory of excess or surplus Federal property. This Notice is also published in order to comply with the December 12, 1988 Court Order in *National Coalition for the Homeless v. Veterans Administration*, No. 88-2503-OG (D.D.C.).

Properties reviewed are listed in this Notice according to the following categories: Suitable/available, suitable/unavailable, suitable/to be excess, and unsuitable. The properties listed in the three suitable categories have been reviewed by the landholding agencies, and each agency has transmitted to HUD: (1) Its intention to make the property available for use to assist the homeless, (2) its intention to declare the property excess to the agency's needs, or (3) a statement of the reasons that the property cannot be declared excess or made available for use as facilities to assist the homeless.